Browse > Home / Stock Buzz / Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering (IDEV, rated BUY)

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering (IDEV, rated BUY)

September 27, 2008

Sept 26, 2008  — Indevus Pharmaceuticals, Inc. indevus pharmaceuticals inc com
( IDEV :)

IDEV   3.17 , +1.44 , +83.2% ) today announced that it has signed a development, license and commercialization agreement with Teva Pharmaceutical Industries Ltd. for the exclusive, worldwide rights to pagoclone. Indevus previously announced promising data from its 8-week, placebo controlled, double-blind, multi-center Phase II trial in patients with persistent stuttering which showed that pagoclone produced a statistically significant benefit in multiple primary and secondary stuttering endpoints compared to placebo. Pagoclone is a novel member of the cyclopyrrolone class of compounds and acts as a gamma amino butyric acid (GABA) selective receptor modulator.

Mentioned on TheSubway.com:  This morning we are looking at Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) for a trade.  IDEV is up nice on news this morning in a bad tape

Indevus Announces Agreement With Teva to Develop Pagoclone for the Treatment of Stuttering (IDEV, rated BUY)

Subscribe To Site:
Full Post Feed | Summary Feed | Comments Feed

Written by admin · Filed Under Stock Buzz 

Comments

RSS feed | Trackback URI

Comments »

No comments yet.

Name (required)
E-mail (required - never shown publicly)
URI
Your Comment (smaller size | larger size)
You may use <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong> in your comment.